TTFields, Taxol Combo Shows Promise in Recurrent Ovarian Cancer Patients

TTFields, Taxol Combo Shows Promise in Recurrent Ovarian Cancer Patients
Patients with recurrent ovarian cancer may greatly benefit from the addition of Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, to Taxol (paclitaxel), according to recent data from the pilot INNOVATE trial. Recent data presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C., has shown

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *